Cargando…
PD-1(+) regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
PD-1 blockade is a cancer immunotherapy effective in various types of cancer. In a fraction of treated patients, however, it causes rapid cancer progression called hyperprogressive disease (HPD). With our observation of HPD in ∼10% of anti–PD-1 monoclonal antibody (mAb)-treated advanced gastric canc...
Autores principales: | Kamada, Takahiro, Togashi, Yosuke, Tay, Christopher, Ha, Danbee, Sasaki, Akinori, Nakamura, Yoshiaki, Sato, Eiichi, Fukuoka, Shota, Tada, Yasuko, Tanaka, Atsushi, Morikawa, Hiromasa, Kawazoe, Akihito, Kinoshita, Takahiro, Shitara, Kohei, Sakaguchi, Shimon, Nishikawa, Hiroyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6525547/ https://www.ncbi.nlm.nih.gov/pubmed/31028147 http://dx.doi.org/10.1073/pnas.1822001116 |
Ejemplares similares
-
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)
por: Kowanetz, Marcin, et al.
Publicado: (2018) -
ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019) -
αvβ3-integrin regulates PD-L1 expression and is involved in cancer immune evasion
por: Vannini, Andrea, et al.
Publicado: (2019) -
Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment
por: Peranzoni, Elisa, et al.
Publicado: (2018) -
Cellular function given parametric variation in the Hodgkin and Huxley model of excitability
por: Ori, Hillel, et al.
Publicado: (2018)